Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

30 results about "Staphylococcus simulans" patented technology

Staphylococcus simulans is a Gram-positive, coagulase-negative member of the bacterial genus Staphylococcus consisting of single, paired, and clustered cocci.

Monoclonal antibodies to the ClfA protein and method of use in treating or preventing infections

InactiveUS6979446B2Avoid stickingInhibiting or impairing the binding of the ClfA proteinAntibacterial agentsBacterial antigen ingredientsBacteroidesStaphylococcus cohnii
Monoclonal antibodies which can bind to the ClfA protein and which are generated from binding subdomains or active fragments of the ClfA protein from Staphylococcus aureus, including the active fragments proteins from its fibrinogen binding domain such as Clf40 protein, the Clf33 protein, or ClfA N3, are provided which can be useful in the treatment and protection against infection from staphylococcal bacteria such as Staphylococcus aureus. In addition, medical instruments can be treated using the monoclonal antibodies of the invention in order to reduce or eliminate the possibility of their becoming infected or further spreading the infection. In particular, the antibodies of the present invention are advantageous because they can prevent adherence of the bacteria to host cells by impairing or inhibiting the ability of S. aureus ClfA to bind to fibrinogen or fibrin, and thus can be utilized in methods or treating or preventing staphylococcal inventions.
Owner:INHIBITEX INC

Nucleic acid encoding endolysin fusion protein

The invention concerns a recombinant nucleic acid molecule encoding an antimicrobial fusion peptidoglycan endopeptidase. The recombinant nucleic acid molecule according to the invention is formed from a nucleic acid encoding a bacterial endopeptidase (lysostaphin) from Staphylococcus simulans and a nucleic acid encoding a second endopeptidase (endolysin) module from Group B streptococcal bacteriophage B30. The encoded fusion endopeptidase has antimicrobial activity and kills both Staphylococcus bacteria and Streptococcus bacteria.
Owner:US SEC AGRI

Staphylococcus aureus phage strain and application thereof

The invention provides a staphylococcus aureus phage strain VB_SavM_JYL01. The staphylococcus aureus phage stain VB_SavM_JYL01 has been preserved in the China Center for Type Culture Collection on 25th March, 2018, the preservation name is Staphylococcus aureus phage VB_SavM_JYL01, and the preservation number is CCTCC M 2018154. The staphylococcus aureus phage strain has a wide lysis spectrum, thus staphylococcus aureus can be lysed, certain staphylococcus epidermidis can also be lysed, host bacteria 206 can be lysed, and staphylococcus clinical strains separated from the environment or fecesof diseased animals can also be lysed; the staphylococcus aureus phage can be used independently or in combination with other substances, and a safe and nontoxic phage disinfecting and killing productis provided for disinfecting and purifying the environment.
Owner:JILIN UNIV

Expression of recombinant mature lysostaphin

A portion of the lysostaphin gene of Staphylococcus simulans has been cloned and overexpressed in the cytoplasm of E. coli to yield lysostaphin, in the absence of preprolysostaphin and prolysostaphin, under the transcriptional control of an IPTG-inducible promoter and a ribosome binding site. IPTG induction of the transformed host cells produces intracellular, soluble, mature lysostaphin (27 kDa), in the complete absence of preprolysostaphin and prolysostaphin. The mature lysostaphin so formed dose not require post-translational modification. The mature lysostaphin so formed can be used treat and prevent staphylococcal infections.
Owner:COUNCIL OF SCI & IND RES +1

Method for extracting staphylococcus aureus antigen, reagent for extracting staphylococcus aureus antigen, and method for assessing staphyloccoccus aureus

ActiveUS20120295812A1Efficiently extract PBP2′Reliably assess whether a specimenChlorine/hydrogen-chlorideOther chemical processesAntigenStaphylococcus cohnii
The invention provides a method for extracting a Staphylococcus aureus antigen which comprises using an extraction reagent with a pH of no higher than 5.0, containing one or more acids selected from among hydrochloric acid, acetic acid, citric acid, phosphoric acid, sulfuric acid and nitric acid, to extract a Staphylococcus aureus antigen comprising a methicillin-resistant Staphylococcus aureus antigen and / or a methicillin-sensitive Staphylococcus aureus antigen, from Staphylococcus aureus in a specimen. The invention further provides a method for assessing Staphylococcus aureus.
Owner:KIKKOMAN CORP

Fermentation agent for Chinese air-dried sausage

The invention discloses a fermentation agent for a Chinese air-dried sausage. The fermentation agent is characterized by consisting of lactic acid bacteria and staphylococcus, wherein the lactic acid bacteria are the combination of Lactobacillus delbrueckii subsp. delbrueckii, Lactobacillus delbrueckii subsp. bulgaricus, Lactobacillus sake, Lactobacillus paralimentarius, Lactobacillus pentosus, Pediococcus acidilactici, Pediococcus dextrinicus and Pediococcus pentosaceus; and the staphylococcus is the combination of Staphylococcus xylosus, Staphylococcus simulans and Staphylococcus sciuri. The fermentation of the air-drying process of sausages is promoted by adding the fermentation agent, so that the sausages can be produced throughout the year regardless of regions, and the quality and stability of the product are improved at the same time.
Owner:YANTAI XIWANG FOOD

Preparation method of exfoliative toxin C (ExhC) proteins of staphylococcus sciuri

The invention relates to a preparation method of exfoliative toxin C (ExhC) proteins of staphylococcus sciuri, which comprises the following steps of: (1) taking staphylococcus sciuri genome DNA as templates, amplifying the overall length of ExhC genes of the staphylococcus sciuri, and cloning the ExhC genes into prokaryotic expression vectors to obtain recombinant plasmids; (2) performing escherichia coli conversion on the recombinant plasmids, and expressing the recombinant plasmids through IPTG (isopropyl thiogalactoside) induced proteins; and (3) extracting the crude extract of the proteins, and purifying ExhC proteins. In the method, the efficient expression of ExhC in escherichia coli is realized successfully through a gene engineering technology, and high-purity and high-concentration ExhC with biological activities is obtained; moreover, the preparation method is simple to operate and low in cost.
Owner:CHINA AGRI UNIV

Kit for detecting staphylococcus hominis

The invention provides a kit for detecting staphylococcus hominis. The kit comprises a guide RNA specifically targeting a staphylococcus hominis rpoB gene, amplification primer pairs, hydrated TwistAmp basic kit reaction drying balls, an LbCas12a protein, a single-stranded DNA probe (ssDNA), a Ribonuclease Inhibitor and a buffer solution. The kit is used for detecting the staphylococcus hominis, the detection specificity is high, and the staphylococcus hominis can be distinguished from other staphylococcocci including staphylococcus aureus, staphylococcus epidermidis, staphylococcus warneri, staphylococcus capitis and staphylococcus haemolyticus. The RNA sequence is used for detection, the consumed time is about 1 hour, no PCR instrument is needed, the requirements for equipment are low and significantly lower than those of a traditional bacterial culture method or PCR sequencing method, and the clinical practical value is high.
Owner:ZHEJIANG UNIV

Broad Spectrum of Streptococcus Lyase and Use Thereof

This invention discloses a lysin that can kill many species of Streptococci. A new lysin, ClyR, was constructed by the gene splicing method. The ClyR can effectively kill different species of Streptococci, including Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus suis, Streptococcus uberis, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus mutans, Streptococcus equi, and various Enterococci and Staphylococcus aureus. ClyR shows good stability and is not sensitive to EDTA and high concentration of NaCl. Moreover, the ClyR is active in a wide range of pH and maintains high activity in pH 5-11. Recombinant protein ClyR is well expressed in E. coli stain BL21 (DE3). High doses of ClyR showed no apparent toxicity in mice. Furthermore, administration of 0.8 mg per mouse once is able to completely protect the mouse infected with lethal doses of Group B Streptococci. The ClyR can be used alone or in combination with different forms of reagents and solutions, for the control of a variety of Streptococci and for the treatment of infections caused by these bacteria. It has a broad application prospect.
Owner:PHAGELUX INC

Method for extracting Staphylococcus aureus antigen, reagent for extracting Staphylococcus aureus antigen, and method for assessing Staphylococcus aureus

ActiveUS8679812B2Efficiently extract PBP2′Reliably assess whether a specimenChlorine/hydrogen-chlorideNitrogen compoundsAntigenStaphylococcus cohnii
The invention provides a method for extracting a Staphylococcus aureus antigen which comprises using an extraction reagent with a pH of no higher than 5.0, containing one or more acids selected from among hydrochloric acid, acetic acid, citric acid, phosphoric acid, sulfuric acid and nitric acid, to extract a Staphylococcus aureus antigen comprising a methicillin-resistant Staphylococcus aureus antigen and / or a methicillin-sensitive Staphylococcus aureus antigen, from Staphylococcus aureus in a specimen. The invention further provides a method for assessing Staphylococcus aureus.
Owner:KIKKOMAN CORP

Kit for detecting staphylococcus haemolyticus

The invention provides a kit for detecting staphylococcus haemolyticus. The kit comprises guide RNA specifically targeting staphylococcus haemolyticus rpoB gene, an amplification primer pair, hydration TwistAmp basic kit reaction drying balls, LbCas12a protein, a single-chain DNA probe (ssDNA), a Ribonuclease Inhibitor and a buffer solution. When the kit is used for detecting the staphylococcus haemolyticus, high detection specificity is achieved, and the staphylococcus haemolyticus can be distinguished from other staphylococcus such as staphylococcus aureus, staphylococcus hominis, staphylococcus warneri, staphylococcus capitis and staphylococcus epidermidis. Meanwhile, when the RNA sequence is used to perform detection, detection time is about 1 hour, a PCR instrument is not needed, equipment requirements are evidently lower than those of a traditional bacterial culture method or a PCR sequencing method, and a high clinical practical value is achieved.
Owner:ZHEJIANG UNIV

Specific lysis of staphylococcal pathogens by bacteriophage phi11 endolysin

The Staphylococcus aureus bacteriophage phi11 endolysin has two peptidoglycan hydrolase domains (endopeptidase and amidase) and a SH3b cell wall-binding domain. In turbidity reduction assays, the purified protein can lyse untreated staphylococcal mastitis-causing pathogens, S. aureus and coagulase negative staphylococci (S. chronogenes, S. epidermis, S. hyicus, S. simulans, S. warneri, and S. xylocus), making it a strong antimicrobial protein and an effective candidate for treating multidrug-resistant staphylococci. Lytic activity is maintained at the pH (6.7) and the ‘free’ calcium concentration (3 mM) of milk. Truncated endolysin-derived proteins, containing just the endopeptidase domain, also lyse staphylococci, in the absence of the SH3b-binding domain.
Owner:US SEC AGRI

Staphylococcus simulans L-RG18 fermentation medium for use and high density culture method

The invention discloses a high density fermentation technology of staphylococcus simulans L-RG18 having good fermentation characteristics and separated from France dry sausage, the high density fermentation technology is a high density culture model comprising optimal control of a fermentation culture medium and fermentation process conditions and repeated in-batch coupling cell cycle, according to the high density fermentation technology, a high density fermentation liquid with the living bacterium number of 3.72*1011 CFU / mL is obtained, and the high density fermentation technology lays a foundation for further studies on preparation of direct-adding type staphylococcus simulans meat starter cultures.
Owner:CHINA AGRI UNIV

Staphylococcus simulans BP10 and application thereof to sausage fermentation

The invention relates to a staphylococcus simulans BP10. The staphylococcus simulans BP10 is preserved in China General Microbiological Culture Collection Center with a preservation number of CGMCC (China General Microbiological Culture Collection Center) No. 16592. The invention also relates to a staphylococcus simulans BP10 suspension and a preparation method thereof. The staphylococcus simulansBP10 is prepared by inoculating the staphylococcus simulans BP10 into a LB (lysogeny broth) culture medium for cultivation and then performing centrifugal collection, washing and sterile water resuspension precipitation. The invention also relates application of the staphylococcus simulans BP10 to sausage fermentation and discloses a sausage fermenting agent. The sausage fermenting agent is composed of a lactobacillus plantarum b-2 suspension and the staphylococcus simulans BP10 suspension as a volume ratio of 3:1. When applied to sausage fermentation, the sausage fermenting agent can improvethe quality of fermented sausage products, increase the flavor of the products, improves the structural texture of the products, shorten the fermentation cycle and improve safety of the products.
Owner:HEBEI UNIVERSITY OF ECONOMICS AND BUSINESS

Staphylococcus warneri and application thereof

The invention discloses staphylococcus warneri classified and named as staphylococcus warneri KR809427. The staphylococcus warneri KR809427 is preserved in the China Center for Type Culture Collection on October 31, 2016, and a preservation number is CCTCC NO:M 2016599. The invention further discloses application of staphylococcus warneri to increase of soil pH value and passivation of soil copper activity and discloses an application bacterial agent. The staphylococcus warneri CCTCC NO:M 2016599 grows fast and is high in resistance to copper, acids, alkalis and salts and capable of remarkably increasing culture medium pH value and reducing effective copper content of soil, thereby being high in potential for remediation of different types of copper contaminated soil.
Owner:SINOSTEEL MAANSHAN INST OF MINING RES +1

Preparation technology of cantonese style sausage

The invention discloses a preparation technology of cantonese style sausage, belonging to field of food processing. The preparation technology of the cantonese style sausage comprises the steps of a. preparation of zymophyte, wherein the zymophyte comprises lactobacillus pentosus, pediococcus acidilactici, staphylococcus xylosus, staphylococcus simulans, micrococcus uarians and staphylococcus epidermidis; respectively culturing strains of the zymophyte for later use; b. preparation of raw materials; c. preparation of ingredients; d. pickling, namely, evenly mixing the raw materials and the ingredients, and then inoculating the strains of the zymophyte in sequence; and e. filling the sausage, and drying to obtain the finished product. After the preparation technology of the cantonese style sausage is adopted, the production time of the cantonese style sausage is greatly shortened, and the yield of the cantonese style sausage is increased; and the specially-made ingredients are adopted, so that the cantonese style sausage prepared by the method is better in flavor compared with the cantonese style sausage prepared by the traditional method.
Owner:KINFOODSE FOOD CO LTD KAIYANG GUIZHOU

Application of Amomum tsao-ko oil to preparation of medicament for treating bacterial infectious disease

The invention provides application of Amomum tsao-ko oil to preparation of medicaments for treating bacterial infectious diseases. The bacteria is coagulase negative staphylococcus, Kurthia gibsonii, megacoccus, corynebacterium, enterococcus faecalis, bacillus, escherichia coli, Pseudomonas, Acinetobacter lwoffii, Chryseobacterium indologenes, Enterobacter cloacae, S.flexneri or proteus vulgaris. The medicine provided by the invention has antibacterial activity against gram positive bacteria and gram negative bacteria, as well as strong inhibitory effect on the resistant strains, and also has good antibacterial effect in vivo; in addition; and the medicament can effectively treat clinical infectious diseases caused by gram positive and gram negative bacteria of various types, and provides a novel clinical medicine choice.
Owner:CHENGDU UNIV OF TRADITIONAL CHINESE MEDICINE

Kit for detecting staphylococcus warneri

The present invention provides a kit for detecting staphylococcus warneri. The kit comprises a guide RNA specifically targeting a staphylococcus warneri rpoB gene, an amplification primer pair, hydration TwistAmp basic kit reaction drying spheres, LbCas12a protein, a single-stranded DNA probe (ssDNA), an ribonuclease inhibitor and a buffer solution. The kit is used for detecting the staphylococcuswarneri and high in detection specificity, and can separate the staphylococcus warneri from other staphylococci, including staphylococcus aureus, staphylococcus hominis, staphylococcus epidermidis, staphylococcus capitis and staphylococcus haemolyticus. At the same time, the use of the RNA sequence for the detection takes about 1 hour, does not require a PCR instrument, has low requirements on equipment, and is significantly lower than a conventional bacterial culture method or a PCR sequencing method and large in clinical practical value.
Owner:ZHEJIANG UNIV

Broad spectrum of Streptococcus lyase and use thereof

This invention discloses a lysin that can kill many species of Streptococci. A new lysin, ClyR, was constructed by the gene splicing method. The ClyR can effectively kill different species of Streptococci, including Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus suis, Streptococcus uberis, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus mutans, Streptococcus equi, and various Enterococci and Staphylococcus aureus. ClyR shows good stability and is not sensitive to EDTA and high concentration of NaCl. Moreover, the ClyR is active in a wide range of pH and maintains high activity in pH 5-11. Recombinant protein ClyR is well expressed in E. coli stain BL21 (DE3). High doses of ClyR showed no apparent toxicity in mice. Furthermore, administration of 0.8 mg per mouse once is able to completely protect the mouse infected with lethal doses of Group B Streptococci. The ClyR can be used alone or in combination with different forms of reagents and solutions, for the control of a variety of Streptococci and for the treatment of infections caused by these bacteria. It has a broad application prospect.
Owner:PHAGELUX INC

Cheese flavour ingredient and method of its production

The present invention relates to a method of manufacturing a cheese flavour ingredient and an ingredient so prepared. The method comprises subjecting a protein in water mixture to proteolysis by a protease enzyme and to fermentation with a physiologically acceptable bacterium of one of the genera Enterococcus, Staphylococcus or Pseudomonas capable of producing a cheese flavour ingredient. The cheese flavour ingredient of the invention has a mixture of flavours and may be used as a component of balanced cheese-like flavour compositions. The present invention also relates to bacterial strains useful in the preparation of such an ingredient, these being Enterococcus faecium, Enterococcus faecalis, Enterococcus casselifavus, Staphylococcus simulans and Pseudomonas putida
Owner:FONTERRA COOP GRP LTD

Staphylococcus aureus fluorescent chromogenic culture medium

The invention discloses a fluorescent chromogenic culture medium for detecting staphylococcus aureus. The fluorescent chromogenic culture medium is prepared from a nitrogen source, a carbon source, sodium chloride and an infectious microbe growth inhibitor. The fluorescent chromogenic culture medium is characterized by further being prepared from staphylococcus aureus chromogenic substrate 4-methyl umbelliferone-p-nitro beta-D-glucoside and beta-D-glucoside, non staphylococcus aureus chromogenic substrate paranitrophenol-alpha-D-galactopyranose and non staphylococcus aureus chromogenic substrate p-nitrophenol beta-D-glucuronide. The fluorescent chromogenic culture medium disclosed by the invention can provide a more convenient chromogenic scheme for distinguishing the staphylococcus aureusfrom other staphylococcus under the situation without color developing aid existence, can effectively distinguish the staphylococcus aureus from a part of non staphylococcus aureus and other infectious microbes and has a better selectivity to the staphylococcus aureus.
Owner:黄增才

Staphylococcus haemolyticus Prophage PhiSH2 Endolysin is Lytic for Staphylococcus aureus

Methicillin-resistant (MRSA) and multi-drug resistant strains of Staphylococcus aureus are becoming increasingly prevalent in both human and veterinary clinics. S. aureus-causing bovine mastitis yields high annual losses to the dairy industry. Treatment of mastitis by broad range antibiotics is often not successful and may contribute to development of antibiotic resistance. Bacteriophage endolysins are a promising new source of antimicrobials. The endolysin of prophage φSH2 of Staphylococcus haemolyticus strain JCSC1435 (φSH2 lysin) shows lytic activity against live staphylococcal cells. Deletion constructs were tested in zymograms and turbidity reduction assays to evaluate the contribution of each functional module to lysis. The CHAP domain exhibited three-fold higher activity than the full length protein. Activity was further enhanced in the presence of bivalent calcium ions. The full length enzyme and the CHAP domain showed activity against multiple staphylococcal strains, including MRSA strains, mastitis isolates, and coagulase negative staphylococcal (CoNS) strains.
Owner:US SEC AGRI

Specific Lysis of Staphylococcal Pathogens by Bacteriophage phi11 Endolysin

InactiveUS20110318328A1Antibacterial agentsPeptide/protein ingredientsStaphylococcus cohniiPeptidoglycan Hydrolase
The Staphylococcus aureus bacteriophage phi11 endolysin has two peptidoglycan hydrolase domains (endopeptidase and amidase) and a SH3b cell wall-binding domain. In turbidity reduction assays, the purified protein can lyse untreated staphylococcal mastitis-causing pathogens, S. aureus and coagulase negative staphylococci (S. chronogenes, S. epidermis, S. hyicus, S. simulans, S. warneri, and S. xylocus), making it a strong antimicrobial protein and an effective candidate for treating multidrug-resistant staphylococci. Lytic activity is maintained at the pH (6.7) and the ‘free’ calcium concentration (3 mM) of milk. Truncated endolysin-derived proteins, containing just the endopeptidase domain, also lyse staphylococci, in the absence of the SH3b-binding domain.
Owner:US SEC AGRI

Screening assays for inhibitors of a staphylococcus aureus siderophore

Isolation of an iron regulated, nme-gene operon (designated sbn) from Staphylococcus aureus (RN6390), responsible for the biosynthesis of staphylobactm, a novel S. aureus siderophore Methods for treating or preventing a disease or condition caused by S. aureus infection, as well as methods for identifying agents that inhibit the biosynthesis of staphylobactm or inhibit the expression of genes in said sbn operon are further disclosed.
Owner:UNIV OF WESTERN ONTARIO
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products